Damoctocog alfa pegol
Damoctocog alfa pegol, sold under the brand name Jivi is a recombinant DNA-derived, Factor VIII concentrate medication used to treat hemophilia A. The most common side effects include headache, cough, nausea and fever. Damoctocog alfa pegol (antihemophilic factor- recombinant pegylated-aucl) was approved for medical use in the United States in August 2018, and in the European Union in November 2018.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Damoctocog alfa pegol
Damoctocog alfa pegol, sold under the brand name Jivi is a recombinant DNA-derived, Factor VIII concentrate medication used to treat hemophilia A. The most common side effects include headache, cough, nausea and fever. Damoctocog alfa pegol (antihemophilic factor- recombinant pegylated-aucl) was approved for medical use in the United States in August 2018, and in the European Union in November 2018.
has abstract
Damoctocog alfa pegol, sold un ...... ropean Union in November 2018.
@en
alternative name
Jivi
@en
CAS number
1363853-26-2
DrugBank
FDA UNII code
BY4TSK952Y
KEGG
Link from a Wikipage to an external page
Wikipage page ID
65,475,016
page length (characters) of wiki page
Wikipage revision ID
981,412,178
Link from a Wikipage to another Wikipage
ATC prefix
B02
@en
ATC suffix
BD02
@en
CAS number
DailyMedID
Damoctocog_alfa
@en
DrugBank
DB14700
@en
KEGG
D10759
@en
legal EU
Rx-only
@en
legal status
Rx-only
@en
legal US
Rx-only
@en
licence EU
yes
@en
pregnancy US
N
@en
routes of administration
synonyms
BAY94-9027, antihemophilic factor , PEGylated-aucl
@en
tradename
Jivi
@en
UNII
BY4TSK952Y
@en
wikiPageUsesTemplate
comment
Damoctocog alfa pegol, sold un ...... ropean Union in November 2018.
@en
label
Damoctocog alfa pegol
@en